JP2016513669A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513669A5
JP2016513669A5 JP2016502268A JP2016502268A JP2016513669A5 JP 2016513669 A5 JP2016513669 A5 JP 2016513669A5 JP 2016502268 A JP2016502268 A JP 2016502268A JP 2016502268 A JP2016502268 A JP 2016502268A JP 2016513669 A5 JP2016513669 A5 JP 2016513669A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
cys
gly
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502268A
Other languages
English (en)
Japanese (ja)
Other versions
JP6561042B2 (ja
JP2016513669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026872 external-priority patent/WO2014160507A1/en
Publication of JP2016513669A publication Critical patent/JP2016513669A/ja
Publication of JP2016513669A5 publication Critical patent/JP2016513669A5/ja
Application granted granted Critical
Publication of JP6561042B2 publication Critical patent/JP6561042B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502268A 2013-03-13 2014-03-13 Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法 Active JP6561042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780914P 2013-03-13 2013-03-13
US61/780,914 2013-03-13
PCT/US2014/026872 WO2014160507A1 (en) 2013-03-13 2014-03-13 Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019017599A Division JP2019123711A (ja) 2013-03-13 2019-02-04 Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法

Publications (3)

Publication Number Publication Date
JP2016513669A JP2016513669A (ja) 2016-05-16
JP2016513669A5 true JP2016513669A5 (OSRAM) 2017-03-30
JP6561042B2 JP6561042B2 (ja) 2019-08-14

Family

ID=50680144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502268A Active JP6561042B2 (ja) 2013-03-13 2014-03-13 Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法
JP2019017599A Pending JP2019123711A (ja) 2013-03-13 2019-02-04 Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019017599A Pending JP2019123711A (ja) 2013-03-13 2019-02-04 Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法

Country Status (26)

Country Link
US (4) US9637534B2 (OSRAM)
EP (1) EP2968461B1 (OSRAM)
JP (2) JP6561042B2 (OSRAM)
KR (1) KR102228921B1 (OSRAM)
CN (1) CN105188733B (OSRAM)
AR (1) AR095437A1 (OSRAM)
AU (2) AU2014243712B2 (OSRAM)
BR (1) BR112015022208A8 (OSRAM)
CA (1) CA2904623A1 (OSRAM)
DK (1) DK2968461T3 (OSRAM)
ES (1) ES2933558T3 (OSRAM)
FI (1) FI2968461T3 (OSRAM)
HR (1) HRP20221447T1 (OSRAM)
HU (1) HUE060464T2 (OSRAM)
IL (2) IL240950B (OSRAM)
LT (1) LT2968461T (OSRAM)
MX (1) MX363533B (OSRAM)
PL (1) PL2968461T3 (OSRAM)
PT (1) PT2968461T (OSRAM)
RS (1) RS63820B1 (OSRAM)
RU (1) RU2692652C2 (OSRAM)
SG (3) SG10201912956YA (OSRAM)
SI (1) SI2968461T1 (OSRAM)
TW (1) TWI631133B (OSRAM)
UY (1) UY35407A (OSRAM)
WO (1) WO2014160507A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
ES2933558T3 (es) 2013-03-13 2023-02-10 Genzyme Corp Proteínas de fusión que comprenden porciones de unión a PDGF y VEGF y métodos de uso de las mismas
EP3010525A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
WO2015140638A1 (en) 2014-03-18 2015-09-24 Korea Advanced Institute Of Science And Technology (Kaist) Glycosylated vegf decoy receptor fusion protein
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA2970384A1 (en) * 2015-03-11 2016-09-15 Allgenesis Biotherapeutics Inc. Fusion protein comprising a ligand binding domain of vegf and pdgf
JP6655718B2 (ja) * 2015-06-28 2020-02-26 オールジェネシス バイオセラピューティクス インコーポレイテッド 血管新生を阻害するための融合タンパク質
CA3005391A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3436484B1 (en) 2016-03-30 2025-10-01 AB Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6849390B2 (ja) * 2016-10-28 2021-03-24 花王株式会社 関節のこわばり改善剤
AU2018350700B2 (en) * 2017-10-16 2025-04-24 Vigeneron Gmbh AAV vectors
WO2019083171A2 (ko) * 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
EP3710483A4 (en) * 2017-11-16 2021-10-20 XL-protein GmbH PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
ES3009668T3 (en) * 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
EP4065150A4 (en) 2019-11-25 2023-12-06 The Regents of the University of California LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION
AU2020396699B2 (en) * 2019-12-04 2024-07-18 Cdmogen Co., Ltd Composition for treating diabetic retinopathy, comprising rAAV containing soluble VEGFR-1 variant cDNA
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN113105558A (zh) * 2021-04-01 2021-07-13 芜湖英特菲尔生物制品产业研究院有限公司 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法
AU2022294194A1 (en) * 2021-06-18 2024-01-04 Ikarovec Limited Retinal disorders
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2024029876A1 (ko) 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
WO2025033876A1 (ko) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 변형된 융합 단백질과 scFv의 결합체 및 이의 용도
WO2025042305A1 (ru) * 2023-08-18 2025-02-27 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующпя слитый белок pdgfra-hfc

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4952515A (en) 1987-05-22 1990-08-28 Polymer Technology International Corp. Method of detection using a test strip having a non particulate dialyzed polymer layer
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
ATE193553T1 (de) 1991-01-31 2000-06-15 Cor Therapeutics Inc Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001092551A2 (en) 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003077796A2 (en) 2002-03-15 2003-09-25 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE602005021811D1 (de) * 2004-09-13 2010-07-22 Genzyme Corp Multimere konstrukte
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE102005020510A1 (de) 2005-04-29 2006-11-09 Basf Ag Verbundelement, insbesondere Fensterscheibe
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN101951925A (zh) * 2008-02-20 2011-01-19 建新公司 血管发生抑制
WO2009120922A2 (en) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
CA2820622A1 (en) * 2010-12-02 2012-06-07 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
ES2933558T3 (es) 2013-03-13 2023-02-10 Genzyme Corp Proteínas de fusión que comprenden porciones de unión a PDGF y VEGF y métodos de uso de las mismas

Similar Documents

Publication Publication Date Title
JP2016513669A5 (OSRAM)
RU2015142999A (ru) Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения
JP7229298B2 (ja) ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
JP7788113B2 (ja) Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途
Hutchings et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Friedrich et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety
JP2023053110A (ja) キメラ抗原受容体、組成物及び方法
JP2017506215A5 (OSRAM)
JP2017538401A5 (OSRAM)
JP2015500811A5 (OSRAM)
JP2011526792A5 (OSRAM)
JP2014524903A5 (OSRAM)
JP2019514358A5 (OSRAM)
JP2020514375A5 (OSRAM)
JP2013506411A5 (OSRAM)
JP2014519830A5 (OSRAM)
JP2020517635A5 (OSRAM)
JP2015501814A5 (OSRAM)
JP2010519931A5 (OSRAM)
JP2010529860A5 (OSRAM)
JP2019500894A5 (OSRAM)
JP2020513754A5 (OSRAM)
JP2018519296A5 (OSRAM)
JP2016539096A5 (OSRAM)
JP2014521313A5 (OSRAM)